Dabigatran PBS listing in jeopardy after Sansom review

Professor Lloyd Sansom’s review of anticoagulants, published today, found more work was needed before new oral anticoagulants (NOACs), such as dabigatran, could be listed on the PBS for the prevention of stroke in atrial fibrillation (AF).

“The net overall benefit of NOACs in clinical practice and the subsequent impact on cost-effectiveness is uncertain at this stage, given the further information about dabigatran use that has become available since the PBAC decision regarding this NOAC in 2011.

“It is recommended that the Minister for Health asks PBAC to review its previous recommendations of NOACs,” it said. Announcing the outcome of the review, Ms Plibersek said she was keen to give patients and clinicians certainty about how NOACs fit into practice and had asked the PBAC to consider the matter last week.

“The committee has advised me that based on the new information that has arisen about this drug’s use in